Search Results

You are looking at 31 - 40 of 179 items for :

  • "acute myeloid leukemia" x
Clear All
Full access

Deborah K. Armstrong

common, but high grades are not. Figure 2. Managing PARPi toxicities: guidelines from Dr. Armstrong's practice. Abbreviations: AML/MDS, acute myeloid leukemia/myelodysplastic syndromes; BP, blood pressure; LFTs, liver function tests; PARPi, PARP

Full access

Phillip G. Febbo, Marc Ladanyi, Kenneth D. Aldape, Angelo M. De Marzo, M. Elizabeth Hammond, Daniel F. Hayes, A. John Iafrate, R. Kate Kelley, Guido Marcucci, Shuji Ogino, William Pao, Dennis C. Sgroi and Marian L. Birkeland

Biomarkers in Acute Myeloid Leukemia Assays Currently Used in Cancer Care For each disease considered by the task force, including glioma, breast cancer, colon cancer, lung cancer, prostate cancer, and acute myelogenous leukemia, tabular data

Full access

Jacqueline N. Poston and Pamela S. Becker

Acute Myeloid Leukemia The 2 key goals of myeloid growth factor (MGF) use in the management of acute myeloid leukemia (AML) have been (1) a theoretical benefit for “priming” to improve efficacy of chemotherapy, and (2) reduction of neutropenia

Full access

Peter L. Greenberg, Eyal Attar, John M. Bennett, Clara D. Bloomfield, Uma Borate, Carlos M. De Castro, H. Joachim Deeg, Olga Frankfurt, Karin Gaensler, Guillermo Garcia-Manero, Steven D. Gore, David Head, Rami Komrokji, Lori J. Maness, Michael Millenson, Margaret R. O’Donnell, Paul J. Shami, Brady L. Stein, Richard M. Stone, James E. Thompson, Peter Westervelt, Benton Wheeler, Dorothy A. Shead and Maoko Naganuma

acute myeloid leukemia (AML). In the general population, the incidence rate of MDS is approximately 5 per 100,000 people per year. 1 , 2 MDS is rare among children/adolescents and young adults, with an incidence rate of 0.2 per 100,000 people per year

Full access

Smith Giri, Shadi Hamdeh, Vijaya Raj Bhatt and James K. Schwarz

the potential benefits of the use of several therapies to treat patients with FLT3 -ITD mutations Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults, with an estimated incidence of 3 cases per 100,000 people. 1

Full access

Shi-Yi Wang, Tiange Chen, Weixiong Dang, Sarah S. Mougalian, Suzanne B. Evans and Cary P. Gross

schematic view of the Markov model is summarized in Figure 2 . Patients entered the model in the recurrence-free state and remained in that state until they developed congestive heart failure (CHF), distant recurrence (DR), or acute myeloid leukemia (AML

Full access

Olga Frankfurt and Martin S. Tallman

, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia . The International Acute Myeloid Leukemia Study Group . Blood 1997 ; 90 : 4710 – 4718

Full access

Jeffrey E. Lancet and Sergio Giralt

The authors have received research funding from Pharmion and are consultants for MGI Pharma. References 1. Surveillance, Epidemiology, and End Results (SEER) Program . Acute myeloid leukemia incidence for 2000-2004 . National

Full access

Nicholas G. Zaorsky, Ying Zhang, Vonn Walter, Leila T. Tchelebi, Vernon M. Chinchilli and Niraj J. Gusani

the greatest absolute number of patients in trials: breast, non–small cell lung cancer (NSCLC), pancreas, acute myeloid leukemia, brain, prostate, melanoma, kidney, myeloma, and colorectal 2. Two facility levels: community and academic 3. Four age

Full access

Peter L. Greenberg

undergo evolution to or toward acute myeloid leukemia (AML). Pathogenetic mechanisms contributing to clinical phenotypes relate to critical molecular and biologic features. This article focuses on recently reported advances that describe major components